|
|
Lexicon Pharmaceuticals Inc (LXRX) |
|
Price: $1.0700
$-0.06 
-5.310%
|
| Day's High:
| $1.13
| Week Perf:
| -12.65 %
|
| Day's Low: |
$ 1.07 |
30 Day Perf: |
-39.2 % |
| Volume (M): |
1,689 |
52 Wk High: |
$ 3.79 |
| Volume (M$): |
$ 1,807 |
52 Wk Avg: |
$2.23 |
| Open: |
$1.11 |
52 Wk Low: |
$1.07 |
|
|
| Market Capitalization (Millions $) |
219 |
| Shares
Outstanding (Millions) |
205 |
| Employees |
219 |
| Revenues (TTM) (Millions $) |
0 |
| Net Income (TTM) (Millions $) |
-131 |
| Cash Flow (TTM) (Millions $) |
38 |
| Capital Exp. (TTM) (Millions $) |
2 |
Lexicon Pharmaceuticals Inc
Lexicon Pharmaceuticals Inc is a biopharmaceutical company that is focused on the discovery, development, and commercialization of innovative therapies for the treatment of various diseases. The company's mission is to improve patient lives by bringing breakthrough medicines to market.
The company was founded in 1995 and is headquartered in The Woodlands, Texas. It has a team of experienced professionals who have a track record of success in drug discovery and development, regulatory affairs, and commercialization.
Lexicon Pharmaceuticals has a diverse pipeline of drug candidates that are being developed for the treatment of various conditions such as diabetes, neuropathic pain, carcinoid syndrome, and irritable bowel syndrome. One of their most advanced drug candidates is sotagliflozin, which is a dual inhibitor of sodium-glucose cotransporter 1 and It is being developed as an adjunct to insulin therapy for type 1 diabetes and as a monotherapy for type 2 diabetes.
Another key drug candidate is telotristat etiprate, which is the first and only FDA-approved treatment for carcinoid syndrome diarrhea. The drug is also being developed for the treatment of refractory carcinoid syndrome and pulmonary arterial hypertension.
In addition to its robust pipeline of drug candidates, Lexicon Pharmaceuticals has strategic collaborations with pharmaceutical and biotech companies such as Sanofi, Ipsen, and Bristol-Myers Squibb. These collaborations provide additional resources and expertise to help the company advance its drug candidates and bring them to market.
Overall, Lexicon Pharmaceuticals is a well-established biopharmaceutical company with a strong commitment to developing innovative treatments for patients with unmet medical needs. Its strong pipeline and strategic collaborations position the company for continued growth and success in the future.
Company Address: 2445 Technology Forest Blvd. The Woodlands 77381 TX
Company Phone Number: 863-3000 Stock Exchange / Ticker: NASDAQ LXRX
| LXRX is expected to report next financial results on November 08, 2023. |
|
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
|
Cannapharmarx Inc
The first quarter of 2023 has shown significant promise for Cannapharmarx Inc, a major player in the pharmaceutical preparations industry. While the company has not revealed any top-line figures yet, industry observers are examining the operating shortfall of $-0.720277 million, shedding light on the positive performance of the firm during this period. By comparing it to previous quarters and assessing other growth indicators, we can anticipate a bullish outlook for Cannapharmarx Inc in the near future.
Reduced Losses and Growing Revenue:
In the first quarter of 2022, Cannapharmarx Inc experienced an operating shortfall of $-0.715558 million. However, with effective cost-cutting measures and revenue growth strategies, the company has managed to improve its financial performance in Q1 2023. The company's losses of $-2.072 million in the first quarter of 2022 have been reduced to $-1.413 million, showcasing a significant improvement in their bottom line. This reduction of losses is indicative of a more efficient and profitable operation.
|
|
Benitec Biopharma Inc
Financial News Report: Benitec Biopharma Inc Reports Loss in Fiscal Year 2023
Benitec Biopharma Inc, a major pharmaceutical preparations company, recently released its financial results for the fiscal interval ending June 30, 2023. The company reported a net loss of $-4.661 million, compared to a deficit of $-5.067 million in the corresponding reporting season a year ago.
In terms of earnings per share (EPS), Benitec Biopharma Inc experienced a decline from $-0.16 per share in the previous reporting season to $-0.17 per share in the current period. However, this is an improvement compared to the earnings of $-0.62 per share a year before the reporting season.
|
|
Kintara Therapeutics Inc
Bearish Outlook for Kintara Therapeutics Inc as Fourth Quarter Earnings Paint a Bleak Picture
The fourth quarter earnings report for Kintara Therapeutics Inc (KTRA) has sent shockwaves through the market as the pharmaceutical preparations sector advisors begin to analyze the data. With an operating profit of $3.349 million, KTRA has failed to disclose its revenue for the April to June 2023 financial reporting period. However, comparisons with the previous year's performance highlight a worrying trend.
In the fourth quarter of 2022, KTRA recorded a significantly higher operating profit of $5.458 million, indicating a sharp decline in operating earnings by -38.64%. This decline is a cause for concern as it reflects a substantial decrease in the company's efficiency and overall financial performance. Furthermore, the management has failed to address the issue of diminishing returns, leading to a net deficit of $-14.66 million and a troubling revenue of $0.00 million in the fiscal period 2023.
|
|
Integrated Biopharma Inc
Integrated Biopharma Inc recently released its financial results for the fiscal period ending June 30, 2023. The report highlights a decrease in revenue, net earnings, as well as a decline in operating and net margins. Additionally, the company's stockpiles remain below the previous year's level. This article aims to outline the key facts from the financial results and provide an analysis of Integrated Biopharma Inc's performance.
Financial Results Overview:
1. Earnings per Share (EPS): In the fiscal period ending June 30, 2023, Integrated Biopharma Inc recorded an EPS of $0.00 per share, compared to $0.05 per share in the same period a year ago. This figure also remained consistent with the preceding reporting period.
|
|
Rezolute Inc
Despite some positive momentum in recent weeks, Rezolute Inc (RZLT) remains an overlooked player in the Major Pharmaceutical Preparations sector. The company's financial numbers paint a gloomy picture, indicating significant operating shortfalls and a net deficit.
In the fourth quarter of 2023, Rezolute Inc reported an operating shortfall of $-14.238 million, demonstrating a worsening financial situation. Although the company has not disclosed its revenue, it is clear that its current revenue figures are not helping to alleviate concerns. Comparing it to the fourth quarter of 2022, where Rezolute Inc reported an operating shortfall of $-11.3 million, it is evident that the company's financial woes have only worsened over time.
The shortfall of $-12.728 million reported in the comparable three months preceding last year is also a cause for concern. The fact that this figure increased from $-9.423 million is alarming and suggests a lack of progress in addressing financial challenges. Additionally, the company reported a net deficit of $-51.79 million, further highlighting its troubled financial state.
|
| Per Share |
Current |
| Earnings (TTM) |
-0.66 $ |
| Revenues (TTM) |
0 $
|
| Cash Flow (TTM) |
0.19 $ |
| Cash |
1.25 $
|
| Book Value |
0.91 $
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
-0.66 $
|
| Revenues (TTM) |
0 $ |
| Cash Flow (TTM) |
0.19 $ |
| Cash |
1.25 $
|
| Book Value |
0.91 $ |
| Dividend (TTM) |
0 $ |
|
|
|
|
